REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Wednesday, March 13, 2024, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI41e6b8f8ab024eefafe43493f6fd0cdf
Webcast: https://edge.media-server.com/mmc/p/7c7bss7i
The press release with the fourth quarter and full year 2023 financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information
Investors:
Jami Taylor, Head of Investor Relations for Coherus
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.98 |
Daily Change: | 0.61 44.16 |
Daily Volume: | 96,767,902 |
Market Cap: | US$227.540M |
December 03, 2024 August 08, 2024 June 27, 2024 May 30, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB